Literature DB >> 19277794

Effectiveness of HSV-tk suicide gene therapy driven by the Grp78 stress-inducible promoter in esophagogastric junction and gastric adenocarcinomas.

Armen Azatian1, Hong Yu, Wande Dai, Fiona I Schneiders, Natalia K Botelho, Reginald V N Lord.   

Abstract

BACKGROUND: The thymidine kinase gene of the herpes simplex virus (HSV-tk) is a suicide gene when administrated with the prodrug ganciclovir (GCV). This study investigated the effectiveness of HSV-tk activation as gene therapy for gastroesophageal junction and gastric adenocarcinomas using either the stress-inducible Grp78 promoter or the murine leukemia virus long-terminal repeat (LTR) promoter.
METHODS: The HSV-tk gene, controlled by either the Grp78 promoter or the LTR promoter, was transduced into the gastroesophageal junction adenocarcinoma cell line SK-GT-5 and the gastric adenocarcinoma cell line MKN-74. Cell viability after exposure to varying concentrations of GCV was compared. The same cell lines were used to develop a nude mouse model for studies of the HSV-tk/GCV effect in vivo. The effect of intraperitoneal GCV injection on growth of the subcutaneous tumors was measured. HSV-TK expression was measured by Western blot and reverse transcription polymerase chain reaction.
RESULTS: Cell viability in vitro was significantly lower in the HSV-tk expressing (HSV-tk+) cells compared to control (no HSV-tk) cells after exposure to GCV. MKN-74tk+ cells were more sensitive to GCV killing than SK-GT-5tk+ cells. After culture with 1 microg/ml GCV for 10 days, MKN-74/tk cells were totally killed, whereas most SK-GT-5/tk cells survived. Cell viability was significantly lower under glucose starvation conditions when HSV-tk expression was regulated by the Grp78 promoter compared with the LTR promoter. MKN-74 tumors formed with HSV-tk+ cells in nude mice were eliminated after administration of GCV for 3 weeks, but GCV had no effect on tumors formed from HSV-tk- cells. Eradication of tumor formed with Grp78-tk cells was faster than that with LTR-tk cells. HSV-TK protein and mRNA were expressed in the transduced, but not the non-transduced tumors.
CONCLUSION: HSV-tk xwith ganciclovir suicide gene therapy results in significant cell killing in gastroesophageal junction and gastric adenocarcinoma cells both in vitro and in vivo, but complete tumor elimination only occurred with the gastric adenocarcinoma cell tumors. The most effective approach in this study used the Grp78 promoter in glucose-starvation stress conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19277794     DOI: 10.1007/s11605-009-0839-1

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  33 in total

1.  Is adenocarcinoma following esophagoduodenostomy without carcinogen in the rat reflux-induced?

Authors:  S Oberg; R V Lord; J H Peters; P Chandrasoma; J Theisen; J A Hagen; S R DeMeester; C G Bremner; T R DeMeester
Journal:  J Surg Res       Date:  2000-06-15       Impact factor: 2.192

2.  Gene therapy for esophageal carcinoma: the use of an explant model to test adenoviral vectors ex vivo.

Authors:  Willem A Marsman; Christianne J Buskens; John G Wesseling; G Johan A Offerhaus; Jacques J G H M Bergman; Guido N J Tytgat; J Jan B van Lanschot; Piter J Bosma
Journal:  Cancer Gene Ther       Date:  2004-04       Impact factor: 5.987

Review 3.  Gene therapy and targeted toxins for glioma.

Authors:  Gwendalyn D King; James F Curtin; Marianela Candolfi; Kurt Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

4.  Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression.

Authors:  Q Zhou; R P Sherwin; C Parrish; V Richters; S G Groshen; D Tsao-Wei; F S Markland
Journal:  Breast Cancer Res Treat       Date:  2000-06       Impact factor: 4.872

5.  Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes.

Authors:  T D Palmer; G J Rosman; W R Osborne; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

Review 6.  p53 gene therapy for esophageal cancer.

Authors:  Hideaki Shimada; Hisahiro Matsubara; Takenori Ochiai
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

7.  Characterization of cell lines established from human gastric-esophageal adenocarcinomas. Biologic phenotype and invasion potential.

Authors:  N Altorki; G K Schwartz; M Blundell; B M Davis; D P Kelsen; A P Albino
Journal:  Cancer       Date:  1993-08-01       Impact factor: 6.860

Review 8.  GRP78 induction in cancer: therapeutic and prognostic implications.

Authors:  Amy S Lee
Journal:  Cancer Res       Date:  2007-04-15       Impact factor: 12.701

9.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors.

Authors:  K W Culver; Z Ram; S Wallbridge; H Ishii; E H Oldfield; R M Blaese
Journal:  Science       Date:  1992-06-12       Impact factor: 47.728

10.  Adenoviral serotypes in gene therapy for esophageal carcinoma.

Authors:  Willem A Marsman; John G Wesseling; Abelkarim El Bouch; Piter J Bosma; J Jan B van Lanschot
Journal:  J Surg Res       Date:  2007-04-09       Impact factor: 2.192

View more
  9 in total

Review 1.  Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential.

Authors:  Amy S Lee
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

2.  Combination of MPPa-PDT and HSV1-TK/GCV gene therapy on prostate cancer.

Authors:  Liming Liang; Wenxiang Bi; Weiwen Chen; Yani Lin; Yuanyuan Tian
Journal:  Lasers Med Sci       Date:  2018-01-06       Impact factor: 3.161

3.  Bicistronic vector for combined expression of the HSVtk killer gene and cytokine GM-CSF gene in cancer cells.

Authors:  I V Alekseenko; E P Kopantzev; T V Vinogradova; E D Sverdlov
Journal:  Dokl Biochem Biophys       Date:  2011 Jul-Aug       Impact factor: 0.788

4.  A Universal Tumor-Specific Promoter for Cancer Gene Therapy.

Authors:  I V Alekseenko; V V Pleshkan; A V Sass; O B Filyukova; E V Snezhkov; E D Sverdlov
Journal:  Dokl Biochem Biophys       Date:  2018-07-14       Impact factor: 0.788

5.  Should peri-gastrectomy gastric acidity be our focus among gastric cancer patients?

Authors:  Lei Huang; A-Man Xu; Tuan-Jie Li; Wen-Xiu Han; Jing Xu
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

Review 6.  Endoplasmic reticulum chaperone glucose-regulated protein 78 in gastric cancer: An emerging biomarker.

Authors:  Yan Wang; Jian-Hong Wang; Xun-Lei Zhang; Xiao-Li Wang; Lei Yang
Journal:  Oncol Lett       Date:  2018-02-26       Impact factor: 2.967

7.  Dual systemic tumor targeting with ligand-directed phage and Grp78 promoter induces tumor regression.

Authors:  Azadeh Kia; Justyna M Przystal; Nastasia Nianiaris; Nicholas D Mazarakis; Paul J Mintz; Amin Hajitou
Journal:  Mol Cancer Ther       Date:  2012-10-10       Impact factor: 6.261

Review 8.  Bacteriophage-derived vectors for targeted cancer gene therapy.

Authors:  Md Zahidul Islam Pranjol; Amin Hajitou
Journal:  Viruses       Date:  2015-01-19       Impact factor: 5.048

9.  Targeted Inhibitory Effect of Nasopharyngeal Carcinoma Cells by Hre2.Grp78 Chimeric Promoter Regulating Fusion Gene TK/VP3.

Authors:  Jin-Yun Li; Wen-Xiao Huang; Jie Chen; Su-Ping Zhao; Yao-Yun Tang
Journal:  Technol Cancer Res Treat       Date:  2019 Jan-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.